FORM	4
------	---

(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] – HARDY REGINALD L		2. Issuer Name and Brickell Biotech,		-	Symbol		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) C/O BRICKELL BIOTECH, INC., 5' CENTRAL AVENUE, SUITE 102		3. Date of Earliest Tr 06/14/2021	ansaction (N	fonth/	Day/Year)	CHAIRMAN OF THE BOARD				
(Street) BOULDER, CO 80301	4	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution Date, if any	Code (Instr. 8)		(A) or Disposed of (D)			Owned Following Reported Transaction(s)		Beneficial	
		(Month/Day/Year)	Code	v	Amount	(A) or (D)	Price		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in SEC 1474 (9-02) this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (a a pute calls warrants options convertible securities)

	(<i>e.g.</i> , puts, caus, warrants, options, convertible securities)														
1. Title of	2.	3. Transaction	3A. Deemed	4.		5. Numb	er	6. Date Exercis	sable and	7. Title and	Amount of	8. Price of	9. Number of	10.	11. Nature
Derivative	Conversion	Date	Execution Date, if	Transact	tion	of Deriva	ative	Expiration Dat	e	Underlying	Securities	Derivative	Derivative	Ownership	of Indirect
Security	or Exercise	(Month/Day/Year)	any	Code		Securitie	s	(Month/Day/Y	ear)	(Instr. 3 and	4)	Security	Securities	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8))	Acquired	l (A)					(Instr. 5)	Beneficially	Derivative	Ownership
	Derivative					or Dispos	sed						Owned	Security:	(Instr. 4)
	Security					of (D)							Following	Direct (D)	
						(Instr. 3,	4,						Reported	or Indirect	
						and 5)							Transaction(s)	< / <	
				Code	v	(A)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Stock Option (right to buy)	\$ 0.90	06/14/2021		А		40,000		06/14/2022	06/14/2031	Common Stock	40,000.00	\$ 0	40,000	D	

Reporting Owners

		Relationships							
Reporting Owner Name / Addres	s Director	10% Owner	Officer	Other					
HARDY REGINALD L C/O BRICKELL BIOTECH, INC. 5777 CENTRAL AVENUE, SUIT BOULDER, CO 80301	x		CHAIRMAN OF THE BOARD						

Signatures

/s/ Christine G. Long, Attorney-in-Fact for Reginald L. Hardy (power of attorney previously filed)	06/14/2021
Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.